Michal Berkner

Cooley advised Clinical Microbiomics, a leading innovator in bioinformatics and systems biology for the microbiome field based in Copenhagen, on its merger with CosmosID, a leading CLIA-certified, GxP-compliant microbiome contract research organization based in Maryland. 

Read more

Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion.

Cooley advised Redx Pharma, a UK clinical-stage biotechnology company, on its all share merger with Jounce Therapeutics, a US clinical-stage immunotherapy company, in a $425 million and contingent value right transaction.

Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines portfolio for up to $380 million, including an upfront payment of $270 million.

Cooley advised Biote, a medical practice-building business within the hormone optimization space, on its definitive business combination agreement with special purpose acquisition company (SPAC) Haymaker Acquisition Corp III. Lawyers Michal Berkner and Jarrett Burks led the Cooley team advising Biote.